Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

248 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03102034

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Usc La Nichd Crs Los Angeles, California, United States
  • David Geffen School of Medicine at UCLA NICHD CRS Los Angeles, California, United States
  • Univ. of Colorado Denver NICHD CRS Aurora, Colorado, United States
  • Emory University School of Medicine NICHD CRS Atlanta, Georgia, United States
View Trial Details
Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Huntington Park, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Nampa, Idaho, United States
View all 32 locations
View Trial Details
Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Anaheim, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Topeka, Kansas, United States
  • GSK Investigational Site Frederick, Maryland, United States
View all 24 locations
View Trial Details
Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Lenexa, Kansas, United States
  • GSK Investigational Site Rochester, New York, United States
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Tampere, Finland
View Trial Details
Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01968083

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • University of California, UC San Diego CRS La Jolla, California, United States
  • Miller Children's Hospital at Long Beach Memorial Medical Center Long Beach, California, United States
  • The Children's Hospital University of Colorado Denver, Colorado, United States
  • Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago, Illinois, United States
View Trial Details

Related conditions